SecBot SecBot
SECBOTREPLAY Home › Report › CGON

CGON · CG Oncology reported Q1 2026 results with a net loss of $0.71 per…

CG Oncology Inc. · PRESS-RELEASE filed May 8, 2026 at 08:30 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed May 8, 2026 at 08:30 ET

CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, slightly wider than the $0.45 loss a year ago, but the headline is the BLA completion timeline for cretostimogene in BCG-unresponsive NMIBC now guided to Q4 2026, with Phase 3 PIVOT-006 topline data expected in H1 2026. The company raised $391.4M via ATM in Q1, boosting cash to $1.1B, sufficient through 2029, and reported first commercial revenue of $1.07M. The stock will move on the BLA timeline clarity and upcoming PIVOT-006 data readout.

  • BLA completion for cretostimogene in HR BCG-unresponsive NMIBC guided to Q4 2026 (previously no specific timeline)
  • Phase 3 PIVOT-006 topline data in intermediate-risk NMIBC expected H1 2026
  • First results from CORE-008 Cohort CX (cretostimogene + gemcitabine) to be presented at AUA May 16, 2026
  • Net loss of $60.2M ($0.71/share) vs $34.5M ($0.45/share) in Q1 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access